Dijklander Ziekenhuis
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Dijklander Ziekenhuis, the Internal Medicine team is involved in studies focused on major cardiovascular diseases, especially acute myocardial infarction, atherosclerotic cardiovascular disease, and inherited cholesterol disorders such as heterozygous familial hypercholesterolemia. The research is aimed at improving prevention, symptom-based treatment, and long-term outcomes for people at risk of serious heart events.
- Testing new approaches for people with suspected or recurrent acute myocardial infarction
- Evaluating treatments that lower LDL cholesterol and reduce cardiovascular risk
- Studying therapies designed to prevent major heart complications in patients with elevated lipoprotein(a)
These trials reflect a strong focus on better heart protection, earlier intervention, and more effective long-term management of high-risk cardiovascular conditions.
Neoplasms
The site also contributes to research in neoplasms, with studies centered on blood cancers such as diffuse large B-cell lymphoma and multiple myeloma. These trials are exploring improved treatment strategies, better disease control, and more precise ways to monitor how patients respond to therapy.
- Assessing new treatment combinations for newly diagnosed diffuse large B-cell lymphoma
- Studying whether added immunotherapy can improve outcomes in aggressive lymphoma
- Comparing methods to track disease burden in multiple myeloma
Research at Dijklander Ziekenhuis in this area is focused on extending remission, improving survival, and refining disease monitoring for patients with complex hematologic malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 10 therapeutic areas and 15 of 108 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 104 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
- 1Amsterdam UMC Stichting7active
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amsterdam UMC Stichting10trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dijklander Ziekenhuis
lock Showing 1 of 36 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Visugromab in Patients with Cancer-associated Cachexia | CatalYm GmbH | Phase IV | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 108 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Lenalidomide | 4 | Unknown | 2022-09-13 | 2024-05-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.